secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001628280-25-021304
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q1 net income $0.3M on $28.8M revenue; XOLREMDI sales $3.5M since launch; 4WARD trial on track
--------------------------------------------------------------------------------

- Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.
- XOLREMDI cumulative U.S. net sales $3.5M since May 2024 launch through March 2025.
- Phase 3 4WARD CN trial full enrollment expected 3Q/4Q 2025; top-line data in 2H 2026.
- Strategic restructuring to cut annual spending by $30-35M; cash $87.7M funds ops into 1H 2026.
- Completed 1-for-30 reverse stock split effective April 28, 2025; shares reduced from ~173.6M to ~5.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/0001628280-25-021304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/xfor-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-021304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer